

Section I. (Amendments to the Specification)

Please amend the specification as follows:

On page 1, please insert below the title, before the heading "TECHNICAL FIELD," the following new paragraph:

PRIORITY CLAIM AND CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed under the provisions of 35 U.S.C. §371 and claims the benefit of priority of International Patent Application No. PCT/KR2005/000356, filed 4 February 2005, which in turn claims priority of Korean Patent Application No.10-2004-0007321, filed 4 February 2004. The disclosures of all said applications are hereby incorporated herein by reference in their respective entireties.

On page 9, please replace the paragraph beginning at line 15 ("FIG. 4 graphically shows the results...") with the following new replacement paragraph:

FIG 4 graphically shows the results of enzyme-linked immunosorbent assay (ELISA) for IgG antibody titers against CPV VP2-1 and CPV VP2-2 antigens in the serum of mice orally and rhinally administered with a Lactobacillus casei strain which has been transformed with each of the inventive surface expression vector pHCE2LB: pgsA: VP2-1 and pHCE2LB: pgsA: VP2-2 and confirmed to have an epitope expressed on its surface. "A" represents IgA antibody titer in the oral administration group, and "B" represents IgA antibody titer in the rhinal administration group.

On page 12, please replace the paragraph beginning at line 4 ("VP2-1 having an amino acid length of 153...") with the following new replacement paragraph:

VP2-1 having an amino acid length of 153 (2nd-[[153rd]] 155th amino acids) was named "CPV VP2-1", and a fragment having an amino acid length of 270 (252nd-522nd amino acids) was named "CPV VP2-2.